3
8. CRT remains recommended for patients with HF, LVEF ≤35%,
LBBB, QRS duration ≥ 150 ms, and New York Heart Association
(NYHA) class II–IV symptoms on guideline-directed medical
therapy (COR 1). New recommendations are made for CSP when
effective CRT cannot be achieved (COR 2a); and for CRT in patients
with select characteristics (eg, female sex), as they may derive
benefit from CRT at QRS durations of 120–149 ms (COR 1). New
recommendations are also made for patients with HF, LVEF 36%–
50%, LBBB, and QRS duration ≥ 150 ms for CRT or CSP to maintain
or improve LVEF (COR 2b).
9. New CPP recommendations are provided for patients with HF,
LVEF ≤ 35%, and non-LBBB pattern for QRS duration both < 150
and ≥ 150 ms (COR 2b).
10. During implantation and follow-up of patients with CPP devices,
electrocardiographic demonstration of BiV (for CRT) or conduction
system (for CSP) capture is essential.
